According to the deep-dive market assessment study by Growth+ Reports, the global chronic pulmonary aspergillosis drugs market is expected to witness a CAGR of ~ 4.8% from 2022 to 2030.
The key driver of the global market for treatments for chronic pulmonary aspergillosis is the increased prevalence of respiratory disorders such as asthma, tuberculosis, lung cancer, etc. A strong product pipeline for CPA is another important aspect driving the expansion of the global market. The overall sum invested in R&D to create new aspergillosis medicines has increased. The key market companies are also utilizing partnerships and acquisition strategies to create new pharmaceuticals, which is boosting the global market's growth. In a manner like this, the continued development of new therapies and the rising public consciousness of the need of treating chronic pulmonary aspergillosis are encouraging the growth of the global market. The strict rules for drug approval and the escalating generic competition, however, are the key factors restricting the expansion of the global industry. The development of drug resistance to antifungal medications and the adverse effects of antifungals, such as itchiness and rashes, among other things, are further obstacles preventing the worldwide market from growing.
Leading international fungal education (LIFE) organizations estimate that approximately three million people worldwide have chronic pulmonary aspergillosis, of whom 1.2 million have had tuberculosis (LIFE). Thus, it is believed that the primary underlying cause of chronic pulmonary aspergillosis is tuberculosis. boosting the market for CPA medications.
One of the key factors driving the growth of the global market is the availability of a strong product pipeline for chronic pulmonary aspergillosis. Many effective medications are now undergoing Phase 3 clinical trials. For instance, Scynexis, Inc. is funding a clinical trial for ibrexafungerp to treat several conditions, including candidiasis, invasive aspergillosis, and chronic pulmonary aspergillosis.
On the other hand, the continuous use of antifungals is linked to a wide range of problems. One of the most important global challenges is the emergence of antifungal medication resistance.
According to projections, the market for medications to treat chronic pulmonary aspergillosis will expand fastest in Asia Pacific. The region's rapid expansion can be mostly linked to elements like the increase in fungal infections, as invasive aspergillosis remains the most prevalent mold infection among immunocompromised individuals in the Asia-Pacific region (IA). Affected are approximately 3,957 individuals or 50% of the 19,615 survivors of pulmonary tuberculosis with CPA in 2012. Japanese investigators have recognized CPA as a problem that has become more prevalent due to the vast number of older people in Japan who have a history of tuberculosis.
The prominent players operating in the global chronic pulmonary aspergillosis drugs market are Pfizer Inc., Merck & Co., Astellas Pharma, Gilead Science Inc., Novartis AG, Johnson & Johnson, F2G Ltd., Scynexis, Inc., and TFF Pharmaceuticals.